CD1d expression in myeloma cells as assessed by immunohistochemistry
| Patient No./year . | Disease status/tissue . | Score . | Localization* . |
|---|---|---|---|
| 1 | |||
| 1998 | Relapse post–auto-HSCT /BM | 1 | C > M |
| 2000 | Relapse post–allo-HSCT/ BM | 1 | C > M |
| 2 | |||
| 1998 | Post-chemo/BM | 2 | C > M |
| 2001 | Pre–allo-HSCT/BM | 3 | C > M |
| 3 | |||
| 1998 | Diagnosis/BM | 2 | C > M |
| 2000 | Relapse post–allo-HSCT/ BM | 2 | C > M |
| 4 | |||
| 1999 | Primary resistance to chemo/BM | 3 | C > M |
| 2002 | Relapse post–allo-HSCT/ BM | 3 | C > M |
| 5 | |||
| 1998 | Diagnosis/BM | 3 | M > C |
| 2002 | Primary resistance to chemo/BM | 3 | C > M |
| 6 | |||
| 1999 | Diagnosis/BM | 2 | C = M |
| 2002 | Chemo-resistant relapse/BM | 2 | C > M |
| 2002 | Terminal disease/BM | 0 | None |
| 7 | |||
| 1998 | Relapse post-chemo/BM | 1 | C > M |
| 1999 | Relapse post–allo-HSCT/ skin plasmacytoma | 0 | None |
| 8 | |||
| 1999 | Diagnosis/BM | 1 | C > M |
| 2003 | Relapse post–allo-HSCT/ BM | 0 | None |
| 9 | |||
| 2003 | Diagnosis/BM | 2 | C > M |
| 2007 | Relapse post–chemo and –auto-HSCT | 2 | C |
| 10 | |||
| 2002 | Diagnosis/BM | 3 | C > M |
| 2006 | Relapse post–chemo and –auto-HSCT/BM | 0 | None |
| 11 | |||
| 2004 | Diagnosis/BM | 2 | M > C |
| 2005 | Post–chemo refractory disease/BM | 0 | None |
| 12 | |||
| 2001 | Diagnosis/ BM | 1 | C > M |
| 2002 | Post–chemo partial response/BM | 0 | None |
| 13 | |||
| 2003 | Diagnosis/ BM | 1 | C > M |
| 2008 | Relapse post–chemo and –auto-HSCT/BM | 0 | None |
| Patient No./year . | Disease status/tissue . | Score . | Localization* . |
|---|---|---|---|
| 1 | |||
| 1998 | Relapse post–auto-HSCT /BM | 1 | C > M |
| 2000 | Relapse post–allo-HSCT/ BM | 1 | C > M |
| 2 | |||
| 1998 | Post-chemo/BM | 2 | C > M |
| 2001 | Pre–allo-HSCT/BM | 3 | C > M |
| 3 | |||
| 1998 | Diagnosis/BM | 2 | C > M |
| 2000 | Relapse post–allo-HSCT/ BM | 2 | C > M |
| 4 | |||
| 1999 | Primary resistance to chemo/BM | 3 | C > M |
| 2002 | Relapse post–allo-HSCT/ BM | 3 | C > M |
| 5 | |||
| 1998 | Diagnosis/BM | 3 | M > C |
| 2002 | Primary resistance to chemo/BM | 3 | C > M |
| 6 | |||
| 1999 | Diagnosis/BM | 2 | C = M |
| 2002 | Chemo-resistant relapse/BM | 2 | C > M |
| 2002 | Terminal disease/BM | 0 | None |
| 7 | |||
| 1998 | Relapse post-chemo/BM | 1 | C > M |
| 1999 | Relapse post–allo-HSCT/ skin plasmacytoma | 0 | None |
| 8 | |||
| 1999 | Diagnosis/BM | 1 | C > M |
| 2003 | Relapse post–allo-HSCT/ BM | 0 | None |
| 9 | |||
| 2003 | Diagnosis/BM | 2 | C > M |
| 2007 | Relapse post–chemo and –auto-HSCT | 2 | C |
| 10 | |||
| 2002 | Diagnosis/BM | 3 | C > M |
| 2006 | Relapse post–chemo and –auto-HSCT/BM | 0 | None |
| 11 | |||
| 2004 | Diagnosis/BM | 2 | M > C |
| 2005 | Post–chemo refractory disease/BM | 0 | None |
| 12 | |||
| 2001 | Diagnosis/ BM | 1 | C > M |
| 2002 | Post–chemo partial response/BM | 0 | None |
| 13 | |||
| 2003 | Diagnosis/ BM | 1 | C > M |
| 2008 | Relapse post–chemo and –auto-HSCT/BM | 0 | None |
HSCT indicates hematopoietic stem cell transplantation; BM, bone marrow; and None; staining not higher than background.
C indicates cytoplasmic staining; and M, membranous staining.